In Vitro Thrombogenicity Evaluation of Hemodialyzers

Area of Science:

• Biomaterials Science
• Medical Device Engineering
• Hemocompatibility Research

Background:

• Dialyzer thrombogenicity is a critical factor in artificial kidney development.
• Novel dialyzer membranes often enhance hydrophilicity to minimize blood clot formation.
• Standardized in vitro testing is essential for reliable hemocompatibility assessment.

Purpose of the Study:

• To characterize the thrombogenicity of the novel FX CorAL dialyzer.
• To identify factors influencing dialyzer thrombogenicity in vitro.
• To propose standardized testing guidelines for dialyzer hemocompatibility.

Main Methods:

• In vitro testing of dialyzers using a human blood recirculation setup.
• Assessment of platelet activation, coagulation, and complement activation markers.
• Evaluation of polysulfone-, polyethersulfone-, and AN69 ST-based dialyzers according to ISO 10993-4 standards.

Main Results:

• The FX CorAL dialyzer exhibited the lowest platelet activation among tested poly(ether)sulfone dialyzers.
• Complement activation was lower for FX CorAL compared to most poly(ether)sulfone and AN69 ST dialyzers.
• No significant differences in plasmatic coagulation were observed across dialyzers.
• Dialyzer type had the most significant impact on thrombogenicity results.

Conclusions:

• The FX CorAL dialyzer shows improved hemocompatibility regarding platelet and complement activation.
• Dialyzer membrane material and design significantly influence thrombogenicity.
• Standardized in vitro testing is crucial for consistent hemocompatibility evaluation and reducing testing heterogeneity.